Zheng Xuejing, Zhang Xinxin, Yu Shengji
Departments of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Heliyon. 2024 Apr 27;10(9):e30457. doi: 10.1016/j.heliyon.2024.e30457. eCollection 2024 May 15.
Organoids are three-dimensional structures derived from primary tissue or tumors that closely mimic the architecture, histology, and function of the parental tissue. In recent years, patient-derived organoids (PDOs) have emerged as powerful tools for modeling tumor heterogeneity, drug screening, and personalized medicine. Although most cancer organoids are derived from primary tumors, the ability of organoids from metastatic cancer to serve as a model for studying tumor biology and predicting the therapeutic response is an area of active investigation. Recent studies have shown that organoids derived from metastatic sites can provide valuable insights into tumor biology and may be used to validate predictive models of the drug response. In this comprehensive review, we discuss the feasibility of culturing organoids from multiple metastatic cancers and evaluate their potential for advancing basic cancer research, drug development, and personalized therapy. We also explore the limitations and challenges associated with using metastasis organoids for cancer research. Overall, this review provides a comprehensive overview of the current state and future prospects of metastatic cancer-derived organoids.
类器官是源自原代组织或肿瘤的三维结构，它们紧密模拟亲代组织的结构、组织学和功能。近年来，患者来源的类器官（PDO）已成为用于模拟肿瘤异质性、药物筛选和个性化医疗的强大工具。尽管大多数癌症类器官源自原发性肿瘤，但转移性癌类器官作为研究肿瘤生物学和预测治疗反应模型的能力是一个活跃的研究领域。最近的研究表明，源自转移部位的类器官可以为肿瘤生物学提供有价值的见解，并可用于验证药物反应的预测模型。在这篇全面综述中，我们讨论了培养多种转移性癌症类器官的可行性，并评估它们在推进基础癌症研究、药物开发和个性化治疗方面的潜力。我们还探讨了使用转移类器官进行癌症研究的局限性和挑战。总体而言，本综述全面概述了转移性癌衍生类器官的现状和未来前景。
